Cited by 181Biosimilars and Bioanalytical MethodsAnalytical Methods in PharmaceuticalsAdvanced Proteomics Techniques and Applications

Recommendations for Validation of LC-MS/MS Bioanalytical Methods for Protein Biotherapeutics

Open access
Jenkins, Rand, Duggan, Jeffrey X., Aubry, Anne-Françoise, Zeng, Jianing, Lee, Jean W., Cojocaru, Laura, Dufield, Dawn, Garofolo, Fabio +7 more·2015·The AAPS Journal

Abstract

This paper represents the consensus views of a cross-section of companies and organizations from the USA and Canada regarding the validation and application of liquid chromatography tandem mass spectrometry (LC-MS/MS) methods for bioanalysis of protein biotherapeutics in regulated studies. It was prepared under the auspices of the AAPS Bioanalytical Focus Group's Protein LC-MS Bioanalysis Subteam and is intended to serve as a guide to drive harmonization of best practices within the bioanalytical community and provide regulators with an overview of current industry thinking on applying LC-MS/MS technology for protein bioanalysis. For simplicity, the scope was limited to the most common current approach in which the protein is indirectly quantified using LC-MS/MS measurement of one or more of its surrogate peptide(s) produced by proteolytic digestion. Within this context, we considered a range of sample preparation approaches from simple in-matrix protein denaturation and digestion to complex procedures involving affinity capture enrichment. Consideration was given to the method validation experiments normally associated with traditional LC-MS/MS and ligand-binding assays. Our collective experience, thus far, is that LC-MS/MS methods for protein bioanalysis require different development and validation considerations than those used for small molecules. The method development and validation plans need to be tailored to the particular assay format being established, taking into account a number of important factors: the intended use of the assay, the test species or study population, the characteristics of the protein biotherapeutic and its similarity to endogenous proteins, potential interferences, as well as the nature, quality, and availability of reference and internal standard materials.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1208/s12248-014-9685-5

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Jenkins, R., Duggan, J. X., Aubry, A.-F., Zeng, J., Lee, J. W., Cojocaru, L., Dufield, D., Garofolo, F., Kaur, S., Schultz, G. A., Xu, K., Yang, Z., Yu, J., Zhang, Y. J., & Vazvaei, F.
Affiliations
  • Pharmaceutical Product Development (United States) (US)
  • Boehringer Ingelheim (United States) (US)
  • Bristol-Myers Squibb (United States) (US)
  • Pfizer (United States) (US)
  • Genentech (US)
  • IQVIA (United Kingdom) (GB)
Corresponding author
Vazvaei, Faye
Venue
The AAPS Journal
Published
2014-11-13
Volume
17
Issue
1
Pages
1-16
ISSN
1550-7416 (ISSN-L)
OpenAlex
W1964595219
Cited by
181
References
27
Citations by year
2026: 9 · 2025: 11 · 2024: 15 · 2023: 9 · 2022: 9 · 2021: 14 · 2020: 18 · 2019: 18 · 2018: 26 · 2017: 23 · 2016: 22 · 2015: 7
FWCI
7.92
Type
journal article
Language
en
Open access
Locations
  • The AAPS Journal (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Pfizer
  • GlaxoSmithKline
  • Biogen
  • Genentech
  • Novartis Institutes for BioMedical Research
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
  • Physical Sciences › Chemistry › Analytical Chemistry › Analytical Methods in Pharmaceuticals
  • Physical Sciences › Chemistry › Spectroscopy › Advanced Proteomics Techniques and Applications
Keywords
method validation, surrogate peptides, proteolytic digestion, sample preparation, method development, reference materials, internal standard, regulatory harmonization
MeSH terms
Animals, Canada, Chromatography, Liquid, Humans, Proteins, United States, Tandem Mass Spectrometry, Validation Studies as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review